vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and Genius Sports Ltd (GENI). Click either name above to swap in a different company.
Genius Sports Ltd is the larger business by last-quarter revenue ($510.9M vs $263.6M, roughly 1.9× BALCHEM CORP). BALCHEM CORP runs the higher net margin — 14.9% vs -12.3%, a 27.2% gap on every dollar of revenue. Over the past eight quarters, Genius Sports Ltd's revenue compounded faster (129.2% CAGR vs 4.9%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Genius Sports is a sports data and technology company that provides data management, video streaming and integrity services to sports leagues, bookmakers and media companies.
BCPC vs GENI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $263.6M | $510.9M |
| Net Profit | $39.2M | $-63.0M |
| Gross Margin | 35.6% | 25.2% |
| Operating Margin | 19.8% | -11.5% |
| Net Margin | 14.9% | -12.3% |
| Revenue YoY | 9.8% | — |
| Net Profit YoY | 16.8% | — |
| EPS (diluted) | $1.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $263.6M | $510.9M | ||
| Q3 25 | $267.6M | $335.4M | ||
| Q2 25 | $255.5M | $215.2M | ||
| Q1 25 | $250.5M | $119.7M | ||
| Q4 24 | $240.0M | $413.0M | ||
| Q3 24 | $239.9M | $285.8M | ||
| Q2 24 | $234.1M | $184.1M | ||
| Q1 24 | $239.7M | $97.2M |
| Q4 25 | $39.2M | $-63.0M | ||
| Q3 25 | $40.3M | — | ||
| Q2 25 | $38.3M | $-47.3M | ||
| Q1 25 | $37.1M | $-25.5M | ||
| Q4 24 | $33.6M | $-85.5M | ||
| Q3 24 | $33.8M | $-47.1M | ||
| Q2 24 | $32.1M | $-35.5M | ||
| Q1 24 | $29.0M | $-25.2M |
| Q4 25 | 35.6% | 25.2% | ||
| Q3 25 | 35.7% | 24.2% | ||
| Q2 25 | 36.4% | 19.1% | ||
| Q1 25 | 35.2% | 10.7% | ||
| Q4 24 | 36.0% | 16.7% | ||
| Q3 24 | 35.6% | 20.5% | ||
| Q2 24 | 35.5% | 18.6% | ||
| Q1 24 | 34.0% | 9.8% |
| Q4 25 | 19.8% | -11.5% | ||
| Q3 25 | 20.4% | -15.3% | ||
| Q2 25 | 20.1% | -21.0% | ||
| Q1 25 | 20.4% | -20.3% | ||
| Q4 24 | 19.8% | -18.0% | ||
| Q3 24 | 20.0% | -13.9% | ||
| Q2 24 | 19.6% | -16.8% | ||
| Q1 24 | 17.4% | -23.7% |
| Q4 25 | 14.9% | -12.3% | ||
| Q3 25 | 15.1% | — | ||
| Q2 25 | 15.0% | -22.0% | ||
| Q1 25 | 14.8% | -21.3% | ||
| Q4 24 | 14.0% | -20.7% | ||
| Q3 24 | 14.1% | -16.5% | ||
| Q2 24 | 13.7% | -19.3% | ||
| Q1 24 | 12.1% | -25.9% |
| Q4 25 | $1.21 | — | ||
| Q3 25 | $1.24 | — | ||
| Q2 25 | $1.17 | — | ||
| Q1 25 | $1.13 | — | ||
| Q4 24 | $1.03 | — | ||
| Q3 24 | $1.03 | — | ||
| Q2 24 | $0.98 | — | ||
| Q1 24 | $0.89 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | $280.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $724.5M |
| Total Assets | $1.7B | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $280.6M | ||
| Q3 25 | $65.1M | $110.2M | ||
| Q2 25 | $65.4M | $110.2M | ||
| Q1 25 | $49.9M | $110.2M | ||
| Q4 24 | $49.5M | $100.3M | ||
| Q3 24 | $73.7M | $100.3M | ||
| Q2 24 | $63.7M | $100.3M | ||
| Q1 24 | $60.3M | $100.3M |
| Q4 25 | $1.3B | $724.5M | ||
| Q3 25 | $1.3B | $572.4M | ||
| Q2 25 | $1.3B | $572.4M | ||
| Q1 25 | $1.2B | $572.4M | ||
| Q4 24 | $1.1B | $573.0M | ||
| Q3 24 | $1.2B | $573.0M | ||
| Q2 24 | $1.1B | $573.0M | ||
| Q1 24 | $1.1B | $573.0M |
| Q4 25 | $1.7B | $1.1B | ||
| Q3 25 | $1.7B | $792.3M | ||
| Q2 25 | $1.7B | $792.3M | ||
| Q1 25 | $1.6B | $792.3M | ||
| Q4 24 | $1.6B | $775.7M | ||
| Q3 24 | $1.6B | $775.7M | ||
| Q2 24 | $1.6B | $775.7M | ||
| Q1 24 | $1.6B | $775.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $67.3M | $81.9M |
| Free Cash FlowOCF − Capex | — | $69.6M |
| FCF MarginFCF / Revenue | — | 13.6% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $33.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $67.3M | $81.9M | ||
| Q3 25 | $65.6M | $-4.8M | ||
| Q2 25 | $47.3M | $-1.2M | ||
| Q1 25 | $36.5M | $-14.6M | ||
| Q4 24 | $52.3M | $14.9M | ||
| Q3 24 | $51.3M | $-9.2M | ||
| Q2 24 | $45.0M | — | ||
| Q1 24 | $33.4M | — |
| Q4 25 | — | $69.6M | ||
| Q3 25 | — | $-14.2M | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-16.0M | ||
| Q4 24 | — | $11.3M | ||
| Q3 24 | — | $-11.6M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 13.6% | ||
| Q3 25 | — | -4.2% | ||
| Q2 25 | — | -2.7% | ||
| Q1 25 | — | -13.4% | ||
| Q4 24 | — | 2.7% | ||
| Q3 24 | — | -4.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.1% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | 1.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
GENI
Segment breakdown not available.
